Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5846528A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Jan 16, 1997 |
| Grant date | Dec 8, 1998 |
| Priority date | — |
| Expiry date | Jan 16, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.